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Abstract
Background: This study was to investigate whether the previously proposed link between Alzheimer’s disease
(AD) and decreased retinal nerve fiber layer thickness could be explained by the relationship between abnormal
CSF profiles and optic nerve head characteristics, focusing on the influence of CSF tau protein on the lamina
cribrosa (LC) thickness (LCT).
Methods: A total of 44 eyes from 18 patients with AD and 26 healthy subjects were subjected to
enhanced-depth-imaging volume scanning of the optic nerve using spectral-domain optical coherence
tomography. The B-scan images were constructed three-dimensionally using maximum intensity projection (MIP),
and the LCT was measured at three locations (superior midperipheral, midhorizontal, and inferior midperipheral) using
the thin-slab MIP images. CSF levels of amyloid β 1-42 peptide, (Aβ1–42), total tau (T-tau) and tau phosphorylated at
threonine 181 (P-tau181P) were measured from CSF samples of each subject. The relationship between the level of CSF
proteins and the LCT was determined using linear regression and fractional polynomial analyses.
Results: Univariate regression analysis revealed that higher CSF levels of T-tau (P = 0.004) and P-tau181P (P = 0.027),
as well as a smaller central corneal thickness (P = 0.032), were significantly associated with a smaller LCT. Multivariate
analysis indicated that only CSF T-tau (P = 0.041) was significantly associated with the LCT. The relationship was well
explained by both linear regression (R2 = 0.179, P = 0.004) and fractional polynomial analysis (R2 = 0.275, P = 0.001).
When we performed an assessment by linear regression with an indicator, the relationship was significant both in
the healthy and AD groups, with a stronger correlation found in the healthy group (regression coefficients = -1.098
vs. -0.280, P = 0.018).
Conclusions: An increased CSF level of T-tau was significantly associated with a thinner LCT in both the healthy and
AD groups. This result suggests that LCT could serve as a potential non-invasive indicator for increased CSF tau. The
clinical meaning of the higher level of CSF T-tau in axonal degeneration of the optic nerve remains to be determined.
Keywords: Tau, Neurodegeneration, Optic nerve head, Lamina cribrosa, Spectral-domain optical coherence
tomography
Background
Tau is a microtubule-associated protein that is most
abundantly found in neurons and astrocytes within the
central nervous system. Tau is known to play a pivotal
role in various neurological pathways, interacting with
signaling pathways that regulate microtubule stability
and axonal transport [1–3]. Dysregulation of tau may
disrupt microtubules, interfere with axon transport mech-
anisms, and be toxic to neurons; thus, the role of tau is
central to many human neurodegenerative diseases, such
as Alzheimer’s disease (AD), which are collectively re-
ferred to as tauopathies [1, 3–5]. An increased level of tau
has also been suggested to be an important biomarker for
AD [6].
The optic nerve is a part of the central nervous system,
and mainly comprises retinal ganglion cell (RGC) axons
that project to the optic chiasm and optic tract and ultim-
ately form synapses at the lateral geniculate nucleus.
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Therefore, the optic nerve could be affected by similar
degenerative processes during neurodegeneration. It has
been suggested that pathogenic mechanisms similar to
those in neurodegenerative diseases may also occur in
retinal degenerative diseases such as glaucoma [5, 7–13].
Studies have suggested a possible role of tau protein in
glaucomatous optic nerve damage. Yoneda et al. [14]
demonstrated an increased level of vitreous tau in patients
with retinal disease or those with glaucoma. Gupta et al.
[15] showed that abnormal tau protein was present in the
human retina with uncontrolled glaucoma. Experimental
studies have also suggested that abnormal tau or tau inclu-
sion in mouse RGCs is associated with reduced axonal
transport [16], increased excitotoxic RGC degeneration
[16], and reduced axonal outgrowth [17], However, the
link between the tau protein and the RGC damage
remains to be determined.
Glaucoma is a progressive optic neuropathy character-
ized by the degeneration of RGC axons. Currently, the
lamina cribrosa (LC) within the optic nerve head (ONH)
is considered the primary site of axonal damage in glau-
coma [18–21]. It has been suggested that structural
changes of the LC may induce damage of the RGC
axons passing through the LC by various mechanisms
[21, 22]. On the other hand, the structural differences of
the LC are thought to be responsible for different effects
of intraocular pressure (IOP) on the RGC axons within
the ONH [21, 22]. It has been reported that the LC is
thinner in glaucomatous eyes than in healthy eyes [23, 24].
Further, eyes with a thinner LC have also been associated
with a worse glaucoma stage [23, 24] and a faster progres-
sion [25].
Considering the anatomical proximity between the
ONH and retrobulbar CSF space, it is possible that the
CSF protein affects the ONH. Given the implication of
the LC in glaucoma pathogenesis and the possible influ-
ence of tau protein in glaucomatous axonal damage, it
would be of interest to know how CSF tau protein is
associated with the structural characteristics of the LC.
The purpose of the present study was to determine the
influence of CSF proteins on the ONH structure, focus-
ing on the relationship between CSF tau and the lamina
cribrosa thickness (LCT).
Methods
This study is based on the Study for the Usefulness and
Standardization of Cerebrospinal Fluid and Plasma
Amyloid Biomarkers in Alzheimer’s Disease, which is an
ongoing prospective study of patients with AD and
healthy participants at the Neurocognitive Behavior
Center in collaboration with the Glaucoma Clinic of
Seoul National University Bundang Hospital. This study
was approved by the Seoul National University Bundang
Hospital Institutional Review Board. Informed written
consent was obtained from all participants or their le-
gally acceptable representatives in accordance with the
Declaration of Helsinki.
Study subjects
The subjects were enrolled by advertisement between
May 2012 and April 2014. The participants included in
the study were either normal or had been diagnosed with
AD based on the National Institute on Aging–Alzheimer’s
Association classification system [26].
Complete ophthalmic examinations were provided to all
subjects, including a visual acuity assessment, Goldmann
applanation tonometry, a refraction test, slit-lamp biomi-
croscopy, gonioscopy, a dilated stereoscopic examination of
the optic disc, fundus photography (Kowa VX-10 fundus
camera; Kowa Company, Tokyo, Japan), central corneal
thickness measurements (Orbscan II; Bausch & Lomb Sur-
gical, Rochester, NY, USA), corneal curvature measure-
ments (KR-1800; Topcon, Tokyo, Japan), axial length
measurements (IOL Master; Carl Zeiss Meditec, Dublin,
CA, USA), and enhanced depth imaging (EDI) spectral-
domain optical coherence tomography (SD-OCT)
(Spectralis OCT; Heidelberg Engineering, Heidelberg,
Germany) scanning of the optic disc and circumpapillary
retinal nerve fiber layer (RNFL). The IOP was measured
three times at 15-minute intervals, and the average of the
three values was recorded as the baseline IOP. The
subjects underwent cerebrospinal fluid (CSF) sampling
with CSF pressure measurement on the same day as the
ophthalmic examination (see ‘CSF sampling and storage’
section).
To be included in the present study, an eye had to
have a best-corrected visual acuity ≥20/40 with a spher-
ical refraction of –8.0 to +5.0 diopters (D), cylinder
correction within ±3.0 D, and a normal appearing optic
disc without glaucomatous optic neuropathy and pallor
or swelling. Eyes with any ocular diseases other than
cataracts or a history of intraocular surgery other than
cataract extraction were excluded. Subjects with a
neurological disease other than AD, history of intracra-
nial surgery, lumbar puncture prior to enrollment in
this study, a condition that could affect the intracranial
pressure (idiopathic intracranial hypotension/hyperten-
sion, intracranial tumors or medications (i.e., tetracyc-
line, rofecoxib, mannitol, carbonic anhydrase inhibitor,
etc.)), contraindication for lumbar puncture (i.e., infec-
tious diseases or infection around the lumbar puncture
site, elongated prothrombin time (International Nor-
malized Ratio >1.7), thrombocytopenia <50,000/mm3,
uremia, hemophilia, or other impairment of the coagu-
lation process), or severe cognitive impairment that
resulted in low cooperability were also excluded. When
both eyes were eligible, one eye was randomly selected
from each subject.
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EDI SD-OCT of the ONH
The ONH was imaged using Spectralis OCT with the EDI
technique. The details of the protocol for scanning the
optic nerve using EDI SD-OCT to evaluate the LC are
described elsewhere [27, 28]. In brief, approximately 75
horizontal and vertical B-scan images covering the optic
disc, 30–34 μm apart (the scan-line distance was deter-
mined automatically by the instrument), were obtained for
each eye. For each section, 42 OCT frames were averaged,
which provided the best trade-off between image quality
and patient cooperation [28].
Measurement of LCT
The LCT was measured at three locations in each eye (the
midhorizontal and the superior and inferior midperipheral
regions of the ONH) using thin-slab maximum intensity
projection (MIP) images. Thin-slab MIP images were used
because they allow a straighter detection of the posterior
LC border [29]. The technique of generating thin-slab
MIP images is described in detail elsewhere [29]. In brief,
three-dimensional volumetric reconstruction of the ONH
was performed from the B-scan images by MIP rendering
using image-processing software (Amira 5.2.2; Visage
Imaging, Berlin, Germany) (Fig. 1a). The thin-slab image
was then obtained by selecting two planes (approximately
64 μm apart) inside the three-dimensional volumetric
image data; only the data within these two planes were
displayed in the thin-slab image (Fig. 1b). The LCT was
measured as the distance between the anterior and poster-
ior borders at the central three points (100 μm between
each point) in each MIP thin-slab image along an axis
perpendicular to the anterior LC surface at the measure-
ment point (Fig. 1c). The measurements obtained from
the three thin-slab images were used to calculate the mean
LCT of the eye.
The LCT was measured using the manual caliper tool
of the Amira 5.2.2 software by two observers (EJL and
DSL) who were masked to the clinical information for
the subject. All measurements were repeated three times
each by the two observers, and the average of the six
values was used for the main analysis.
CSF sampling and storage
The CSF was obtained using the fluoroscopy-guided
lumbar puncture technique on the same day as the oph-
thalmic examination [30]. In brief, the participants were
positioned in the lateral decubitus position with their neck
bent in full flexion and the knees bent in full flexion up to
the chest. A standard spinal needle (90 mm length, 20-
gauge) was inserted into the subarachnoid space at the
L3/L4 or L4/L5 interspace under fluoroscopic guidance. A
manometer was connected to a three-way stopcock, and
the opening pressure was measured after the column was
allowed to equilibrate. CSF sampling was then performed
according to a standard protocol [31]. In total, two frac-
tionated CSF samples of 1 and 10–25 ml were collected in
separate polypropylene vials. For the macroscopically
hemorrhagic CSF samples, additional CSF fractions were
collected. All of the CSF examinations were performed by
an experienced radiologist (JWL) who was masked to the
clinical information for the subject.
The first fraction (1 ml) was used for routine examin-
ation of the CSF, which included a cell count and total
protein and glucose analysis. Whenever the CSF cell count
revealed more than 5 white blood cells or more than 50
red blood cells per mm3, the samples were not included in
the study (this criterion did not apply to any of the
samples). The second fraction (10–25 ml) was used for
biomarker analysis. This fraction was centrifuged immedi-
ately after sampling (10 minutes at 2000 x g), and the
supernatant was distributed in different polypropylene
vials and frozen in liquid nitrogen. The CSF samples were
then stored at −80 °C until analysis.
CSF analysis
Prior to the CSF analysis, the samples were randomized to
obtain a proportional distribution of samples from con-
trols and AD patients on each microtiter plate (40 samples
per plate). The laboratory technician was blinded to the
Fig. 1 Measurement of the LCT. a MIP volumetric image reconstructed from B-scan images obtained using SD-OCT. Light-blue lines indicate the
locations where the thin volumetric sections were obtained. b Thin-slab MIP image obtained at the center of the ONH (blue line indicated with
arrowheads in a). c X–Y view of the thin-slab MIP image. The anterior and posterior borders of the LC were defined as the plane that best
represented the margin of the hyper-reflective plate within the 200 μm wide area near the center of the Bruch’s membrane opening. The LCT
was determined by measuring the distance between the anterior and posterior borders of the LC at three locations (red glyphs)
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expected test outcome in terms of clinical and definitive
pathological diagnoses while performing and interpreting
the tests.
The CSF levels of amyloid-beta 1–42 peptide (Aβ1–42),
total tau (T-tau), and tau phosphorylated at threonine
181 (P-tau181P) were determined with INNO-BIA Alz-
Bio3 (INNOGENETICS N.V., Gent, Belgium) using
Luminex® 200™ (Luminex, Austin, TX, USA). With each
assay, the clinical samples together with a blank (sample
diluent), the prepared calibrator solutions, and the ap-
propriate controls were tested strictly following the test
instructions provided in the kit inserts. All samples were
run in duplicate.
If the duplicate results differed by more than 20 % or if
the concentrations obtained were out of range, the samples
were retested. The concentration ranges of the test kits are
described in the package inserts (P-tau181P, 9–264 pg/ml; T-
tau, 22–1289 pg/ml; and Aβ1–42, 56–1710 pg/ml).
Statistical analysis
To measure the interobserver reproducibility of meas-
urement of the LCT, the intraclass correlation coeffi-
cients (ICC) and their 95 % confidence intervals (CIs)
were calculated. The Shapiro–Wilk normality test was
performed because of the relatively small number of
subjects in this study. Comparison between groups for
continuous variables was performed using the
independent-samples t test for parameters that passed
normality tests, and the Mann–Whitney U test was
performed for parameters that did not pass normality
tests. For categorical variables, Pearson’s chi-square test
and Fisher’s exact test were performed for parametric
and nonparametric comparisons, respectively. Linear re-
gression analysis was performed to reveal the factors
that influenced the LCT, including age, IOP, central cor-
neal thickness, axial length, CSF pressure, and CSF
proteins (Aβ1–42, T-tau, and P-tau181P), first with a uni-
variate model and then with a multivariate model that
included variables from the univariate model for which
P <0.10. Statistical analyses were performed with Statis-
tical Package for the Social Sciences software for Win-
dows version 17.0 (SPSS, Inc., Chicago, IL, USA). For
the factors that showed a significant relationship with
the LCT, fractional polynomial analysis [32] was per-
formed using STATA (version 10.0; StataCorp, College
Station, TX, USA) to investigate whether the relationship
could be better explained by a nonlinear model. The
level of statistical significance was set at P <0.05.
Results
The study initially included 52 subjects (22 AD patients
and 30 healthy subjects). Of these, eight subjects were
excluded because of a diagnosis of concurrent glau-
coma (n = 3), a poor B-scan quality that did not allow
delineation of the LC borders (n = 1), poor cooperation
during the SD-OCT examination (n = 2), and failure to
receive a CSF examination (n = 2), yielding a final sam-
ple of 18 AD patients and 26 healthy subjects.
The final subject sample (19 men and 25 women)
were aged 66.0 ± 8.3 years (mean ± standard deviation)
and had a spherical error of 0.5 ± 1.9 D. A comparison
of the baseline clinical characteristics between the AD
and healthy groups is presented in Table 1. The patients
with AD were significantly older (69.7 ± 7.6 vs. 63.4 ±
8.0 years, P = 0.012) and had a lower total Mini-Mental
Status Examination (MMSE) score (19.5 ± 3.7 vs. 29.0 ±
1.3, P <0.001) than the healthy subjects. There were no
significant differences between the AD and healthy
groups for any of the other baseline characteristics,
including gender, spherical error, central corneal thick-
ness, axial length, baseline RNFL thickness, body mass
index, and the presence of diabetes or hypertension
(Table 1).
Table 2 presents a comparison of the CSF analysis
and the LCT between the AD and healthy groups. The
CSF pressure was higher in the healthy group than in
the AD group, but the difference was nonsignificant
(14.4 ± 2.5 vs. 12.8 ± 2.6 mmHg, P = 0.062; Table 2).
There were significant differences between the groups
for all of the CSF proteins analyzed; the AD group had
a lower Aβ1–42 level (306.52 ± 116.21 vs. 463.46 ±
124.69 pg/ml, P <0.001), a higher T-tau level (110.04 ±
57.08 vs. 62.51 ± 19.73 pg/ml, P <0.001), and a higher
P-tau181P level (51.66 ± 19.40 vs. 28.07 ± 14.14 pg/ml, P
<0.001) than those of the healthy group (Table 2). The
interobserver ICC for LCT measurement was 0.926
(95 % CI, 0.901–0.945). No significant differences were
found between the groups in any of the superior, cen-
tral, inferior, and mean LCT measurements (Table 2).
Table 3 presents the factors associated with the
LCT. The univariate analysis revealed a significant in-
fluence of higher levels of CSF T-tau (P = 0.004) and
CSF P-tau181P (P = 0.027) and a thinner central cor-
neal thickness (P = 0.032) on thinner LCT measure-
ments. In the multivariate analysis, only the CSF T-
tau level (P = 0.041) was significantly associated with
the LCT (Table 3). The relationship was significant for
both a linear model (R2 = 0.179, P = 0.004; Fig. 2a, dotted
line) and a nonlinear model (R2 = 0.275, P = 0.001; Fig. 2a,
solid line). The linear model explained the relationship
between the CSF T-tau and the LCT as the following:
y ¼ 272:385−0:3255  x
The best-fitting nonlinear model described the rela-
tionship as the following:
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y ¼ 229:9þ 6849  x−2−0:000002  x3
where y is the LCT measured in micrometers and x is the
level of CSF T-tau measured in pictograms per milliliter.
Regression analysis with an indicator [33] was performed
using the diagnostic group (healthy and AD groups) as an
indicator variable. This analysis was performed using the R
statistical language version 2.15.1 (http://www.R-project.org
(accessed 3 December 2014)). This analysis showed that the
association between CSF T-tau protein and the LCT was
significant in both the healthy and AD groups, with a stron-
ger association found in the healthy group (regression coef-
ficients =–1.098 vs. –0.280, P = 0.018; Fig. 2b).
Representative cases
Figure 3 shows representative cases illustrating the rela-
tionship between the CSF level of T-tau and the LCT.
The LCT is notably thinner in the eye from the AD
group, in which the T-tau protein level in the CSF was
235.2 pg/ml (Fig. 3b), than in the eye from the healthy
group, in which the T-tau level was 27.4 pg/ml (Fig. 3a).
Discussion
The LC comprises connective tissue plates that mainly
include extracellular matrix (ECM) (i.e., collagen fibers,
elastic fibers, basement membranes, and proteoglycans)
and a smaller subset of cellular components (i.e., LC cells,
astrocytes, and microglial cells). The LC is thought to
Table 1 Subjects’ clinical characteristics
AD group (n = 18) Healthy group (n = 26) P value
Gender (male:female)a 7:11 12:14 0.760
Age (years)b 69.7 ± 7.6 63.4 ± 8.0 0.012
Baseline IOP (mmHg)c 11.5 ± 2.8 12.9 ± 2.5 0.262
SE (D)c 0.1 ± 2.2 0.7 ± 1.6 0.567
Central corneal thickness (μm)b 559.6 ± 30.4 572.1 ± 33.6 0.207
Axial length (mm)b 23.6 ± 1.0 23.8 ± 1.0 0.519
RNFL thickness (μm)b 102.7 ± 12.1 100.0 ± 12.3 0.474
Total MMSE scorec 19.5 ± 3.7 29.0 ± 1.3 <0.001
BMI (kg/m2)b 23.9 ± 3.3 23.8 ± 2.4 0.957
Presence of diabetes mellitusa 3 (16.7 %) 5 (19.2 %) 1.000
Presence of systemic hypertensiona 10 (55.6 %) 9 (34.6 %) 0.222
Data are presented as the mean ± standard deviation unless otherwise specified. Statistically significant values are shown in bold
aComparisons were made using Fisher’s exact test
bComparisons were made using an independent-samples t test
cComparisons were made using a Mann–Whitney U test
AD Alzheimer’s disease, BMI Body mass index, IOP intraocular pressure, MMSE Mini-Mental Status Examination, RNFL retinal nerve fiber layer, SE
spherical equivalent
Table 2 Comparison of CSF analysis and LCT measurements between AD and healthy groups
AD group (n = 18) Healthy group (n = 26) P value
CSF analysis
CSF pressure (mmHg)a 12.8 ± 2.6 14.4 ± 2.5 0.062
Aβ1–42 (pg/ml)a 306.52 ± 116.21 463.46 ± 124.69 <0.001
T-tau (pg/ml)b 110.04 ± 57.08 62.51 ± 19.73 <0.001
P-tau181P (pg/ml)
b 51.66 ± 19.40 28.07 ± 14.14 <0.001
LCT measurements
Superior LCT (μm)a 227.61 ± 42.07 238.81 ± 42.08 0.390
Central LCT (μm)a 267.72 ± 31.35 262.65 ± 49.05 0.701
Inferior LCT (μm)b 232.00 ± 45.67 242.27 ± 46.60 0.423
Average LCT (μm)a 242.46 ± 31.93 247.95 ± 37.55 0.616
Data are presented as the mean ± standard deviation, unless otherwise specified. Statistically significant values are shown in bold
aComparisons were made using an independent-samples t test
bComparisons were made using a Mann–Whitney U test
Aβ1–42 amyloid β1–42, AD Alzheimer’s disease, CSF cerebrospinal fluid, LCT lamina cribrosa thickness, P-tau181P, phosphorylated tau181P, T-tau total tau
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provide structural and metabolic support to the RGC
axons passing through it.
It has been suggested that eyes with thin LC are more
susceptible to mechanical damage of the RGC axons. Thin-
ning of the LC may expose the axon to a steep transition
between the IOP and the retrolaminar tissue pressure
(translaminar pressure gradient) and significantly influence
the axoplasmic flow [22, 34–36], causing further axonal
damage. However, it is not fully understood whether some
eyes have inherently thin LC, or the LC is thinned in the
process of degeneration such as physiologic aging or patho-
logic neurodegeneration such as glaucoma.
The present study suggests a potential mechanism of
LC thinning associated with tau pathology; a higher level
of CSF tau was associated with a thinner LC both in
healthy individuals and in patients with AD. To the best of
the authors’ knowledge, this is the first study to reveal a re-
lationship between CSF proteins and the LC characteristics.
Whether CSF tau is a causal factor for thinning of the LC
or a consequence of LC thinning is unclear. Several possi-
bilities may be considered for this issue. First, it is possible
that the CSF tau is a causal factor in LC thinning. The
cytoplasm of astrocytes contains networks of filamentous
proteins, such as the actin cytoskeleton, intermediate fila-
ments, and microtubules that maintain tissue and cell
integrity, cell mobility, and cell differentiation [37]. It has
been suggested that the accumulation of tau contributes
to the collapse of the cytoskeleton and degeneration of
Table 3 Factors associated with the lamina cribrosa thickness
Univariate analysis Multivariate analysis VIF
β 95 % CI P value β 95 % CI P value
Gender, male 5.769 –15.954, 27.493 0.595
Age, per 1 year older –1.103 –2.371, 0.165 0.087 –0.572 –1.746, 0.601 0.330 1.086
Aβ1–42, per 1 pg/ml larger –0.024 –0.100, 0.052 0.521
T-tau, per 1 pg/ml larger –0.326 –0.543, –0.108 0.004 –0.362 –0.709, –0.016 0.041 2.843
P-tau181P, per 1 pg/ml larger –0.582 –1.095, –0.069 0.027 0.166 –0.627, 0.958 0.674 2.882
CSF pressure, per 1 mmHg higher 0.593 –3.526, 4.712 0.773
Total MMSE score, per 1 point higher 0.894 –1.108, 2.896 0.373
IOP, per 1 mmHg higher 0.294 –3.737, 4.325 0.884
Spherical error, per 1 D larger 0.024 –5.983, 6.032 0.994
Global RNFL thickness, per 1 μm thicker 0.930 –0.025, 1.886 0.056 0.845 –0.020, 1.709 0.055 1.113
Central corneal thickness, per 1 μm thicker 0.349 0.032, 0.666 0.032 0.216 –0.091, 0.524 0.163 1.145
Axial length, per 1 mm longer 3.516 –7.861, 14.893 0.536
Statistically significant values are shown in bold
Aβ1–42 amyloid β1–42, CI confidence interval, CSF cerebrospinal fluid, IOP intraocular pressure, MMSE Mini-Mental Status Examination, P-tau181P phosphorylated
tau181P, RNFL retinal nerve fiber layer, T-tau total tau, VIF variance inflation factor
Fig. 2 Scatterplots showing the relationship between the cerebrospinal fluid level of total tau (T-tau) protein and the lamina cribrosa thickness
(LCT). a Linear regression (dotted line) and fractional polynomial (FP) analysis (solid line) performed across all subjects. b Regression analysis with an
indicator was performed using the diagnostic group (healthy vs. Alzheimer’s disease (AD) groups) as an indicator
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astrocytes [38]. When increased CSF tau influences the
stability of the cytoskeleton of laminar astrocytes, the
astrocytes may become more susceptible to degradation,
leading to further thinning of the LC. Second, elevated
CSF tau may be a result caused by a neurodegenerative
cascade facilitated by the thin LC. A thinner LC is associ-
ated with a steeper translaminar pressure gradient that
causes the axons passing through the LC to experience an
abrupt transition between the high IOP and low retrola-
minar pressure. Under these conditions, axonal flow can
be interrupted [34–36], and this effect may result in the
dysregulation of neurotrophic factors [39, 40], which may
in turn increase abnormal tau [41–43]. Finally, however, it
is also possible that LC thinning is simply an epiphenom-
enon accompanied by an elevation in CSF tau associated
with neurodegenerative processes. The result of this study
does not fully explain the causal relationship between the
LCT and CSF tau protein; a long-term investigation of
larger samples is required to address this issue.
In the present study, more than half of the subjects were
healthy individuals; thus, it is not known whether the
non-AD subjects with a thin LC or an elevated CSF tau
had subclinical AD. Although data were not presented be-
cause of the small number of samples, a subgroup analysis
performed within the healthy group revealed a marginal
but not significant linear association of a lower total
MMSE score with thinner LCT (β = 10.417, P = 0.061).
This may indicate that the LCT could also serve as a
potential candidate marker representing cognitive func-
tion as well as the CSF tau level. A long-term follow-up
study is required to verify whether these subjects are more
susceptible to developing AD. Additionally, a study that
includes subjects with mild cognitive impairment may
help to answer this question.
Interestingly, the relationship between the level of CSF
tau and the LCT was significant both in the healthy and
AD groups, with a stronger relationship found in the
healthy group. Although we do not have a clear explan-
ation for this differential correlation between groups, the
smaller span of LCT change relative to that of CSF tau
level in AD patients might be because of the increased
stiffness of the LC tissue in this group, which is associ-
ated with older age [44–46]. On the other hand, a rela-
tively larger span of LCT change despite the smaller
span of CSF tau level in healthy subjects may indicate
that the LCT can serve as a useful marker to monitor
subclinical CSF tau increases.
Thus far, the pathogenic influence of tau has mainly
been centered on the degeneration of axonal tissue. If
this assumption also holds true for RGC degeneration,
the CSF tau level should be associated with the number
of RGC axons, which is represented by the RNFL thick-
ness. However, in the present study, increased tau was
associated only with a smaller LCT and not with a thin-
ner RNFL (data not presented). Instead, a smaller LCT
was correlated with both higher CSF tau levels and a
thinner RNFL. This finding suggests that CSF tau is
more likely associated with glial tissues (LC) than with
neural tissues (RGC axons), and the change in the neural
tissues might be secondary to that in the glial tissues.
This finding supports the assumption that glial cells are
more directly associated with neurodegeneration than
are neuronal cells [47–49].
In the present study, only the T-tau, not the P-tau181P,
was associated with the LCT. Although we do not have
a clear reason for this result, it is possible that the level
of P-tau181P was not sufficiently high to produce a statis-
tical significance. We speculate that other forms of tau
phosphorylation could be more highly associated with
the LCT. However, the original study (Study for the
Usefulness and Standardization of Cerebrospinal Fluid
and Plasma Amyloid Biomarkers in Alzheimer’s Disease)
did not analyze other types of CSF proteins besides Aβ1–
42 and P-tau181P. Further study is expected to reveal the
Fig. 3 Representative images of eyes from the healthy group a and the AD group b. a, b Enface view of the MIP volumetric image. Blue lines
indicate the location where the central thin slab MIP images were obtained. a-1, b-1 Thin-slab MIP images obtained at the center of the ONH
(blue lines). a-2, b-2 Same images as in a-1 and b-1 with labels. Red glyphs indicate the anterior and posterior borders of the LC. The CSF level of
T-tau protein was 27.4 pg/ml a and 235.2 pg/ml b. Note that the LC is notably thinner in b, where the CSF T-tau level was increased
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precise relationship between the phosphorylated tau and
LC characteristics.
In the present study, the Aβ1–42 level was not associated
with the LCT. It is acknowledged that the concentration
of Aβ1–42 in the CSF increases initially but then decreases
decades before the expected onset of symptoms [50–52],
whereas the concentrations of CSF tau are increased
several years before symptoms develop [50–52] and
further increase with the disease progression [53, 54]. In
this context, the nonassociation between the CSF Aβ1–42
and the LCT and the association between CSF tau and the
LCT may suggest that the LCT could serve as a potential
clinical indicator for neurodegeneration in patients with
AD or those at risk of developing AD.
This study is limited by the small sample size and its
cross-sectional design. Hence, a causal relationship between
CSF tau and the LCT and the pathogenic significance of
this potential relationship could not be determined. A long-
term follow-up study with a larger number of subjects,
including subjects with RGC pathology, such as glaucoma,
is needed to reinforce the findings of this study.
Conclusions
The present study found that an increased CSF tau level is
associated with a thin LC in healthy subjects and in
patients with AD. Given the implications of LC thinning
in RGC axonal degeneration, it is possible that tau protein
contributes to a common pathogenesis of neurodegenera-
tion in the brain and optic nerve. In addition, the LCT
could serve as a non-invasive potential biomarker for esti-
mating the level of CSF tau protein and for suspecting the
presence of tauopathies. Although the study leaves many
questions, its results may provide a better understanding
of the mechanisms of tauopathy in neurodegenerative
diseases and a basis for future studies investigating the
pathogenesis of neurodegeneration in the brain and optic
nerve.
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